WO2002096349A3 - Vaccination contre le virus de l'immunodeficience feline - Google Patents

Vaccination contre le virus de l'immunodeficience feline Download PDF

Info

Publication number
WO2002096349A3
WO2002096349A3 PCT/FR2002/001809 FR0201809W WO02096349A3 WO 2002096349 A3 WO2002096349 A3 WO 2002096349A3 FR 0201809 W FR0201809 W FR 0201809W WO 02096349 A3 WO02096349 A3 WO 02096349A3
Authority
WO
WIPO (PCT)
Prior art keywords
gag
fiv
vaccine
pro
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/001809
Other languages
English (en)
Other versions
WO2002096349A2 (fr
Inventor
Laurent Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60236943T priority Critical patent/DE60236943D1/de
Application filed by Merial SAS, Merial Inc filed Critical Merial SAS
Priority to DK02740841.8T priority patent/DK1418941T3/da
Priority to EP02740841A priority patent/EP1418941B9/fr
Priority to BRPI0210229A priority patent/BRPI0210229B1/pt
Priority to JP2002592862A priority patent/JP2004535406A/ja
Priority to AT02740841T priority patent/ATE473013T1/de
Priority to CA2448620A priority patent/CA2448620C/fr
Priority to PL365742A priority patent/PL210450B1/pl
Priority to AU2002314274A priority patent/AU2002314274B2/en
Publication of WO2002096349A2 publication Critical patent/WO2002096349A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002096349A3 publication Critical patent/WO2002096349A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un kit de vaccination des félidés contre FIV, comprenant, conditionnés séparément: un premier vaccin comprenant, dans un véhicule ou excipient pharmaceutiquement acceptable, un plasmide contenant et exprimant in vivo un polynucléotide codant pour env et/ou gag et/ou gag/pro de FIV, un deuxième vaccin comprenant, dans un véhicule ou excipient pharmaceutiquement acceptable, un vecteur viral contenant et exprimant in vivo un polynucléotide codant pour env et/ou gag et/ou gag/pro de FIV,avec la condition selon laquelle au moins l'une des protéines env ou gag ou gag/pro est codée à la fois par les plasmides et par les vecteurs viraux. Utilisation des plasmides et/ou vecteurs viraux pour la préparation de vaccins contre le FIV.
PCT/FR2002/001809 2001-06-01 2002-05-29 Vaccination contre le virus de l'immunodeficience feline Ceased WO2002096349A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL365742A PL210450B1 (pl) 2001-06-01 2002-05-29 Zestaw do szczepienia kotowatych przeciwko wirusowi nabytego niedoboru immunologicznego kotów (FIV) oraz zastosowanie plazmidów i wektorów wirusowych zawierających i eksprymujących in vivo polinukleotydy do wytwarzania szczepionki
DK02740841.8T DK1418941T3 (da) 2001-06-01 2002-05-29 Induktion af immunrespons mod felint immundefektvirus
EP02740841A EP1418941B9 (fr) 2001-06-01 2002-05-29 Induction de reponse immunitaire contre le virus de l'immunodeficience feline
BRPI0210229A BRPI0210229B1 (pt) 2001-06-01 2002-05-29 kit de vacinação, usos de plasmídeos e uso de vetores virais
JP2002592862A JP2004535406A (ja) 2001-06-01 2002-05-29 ネコ免疫不全性ウイルスに対するワクチン
DE60236943T DE60236943D1 (de) 2001-06-01 2002-05-29 Induzierte immunantwort gegen den katzen-immunschwäche-virus
CA2448620A CA2448620C (fr) 2001-06-01 2002-05-29 Vaccination contre le virus de l'immunodeficience feline
AT02740841T ATE473013T1 (de) 2001-06-01 2002-05-29 Induzierte immunantwort gegen den katzen- immunschwäche-virus
AU2002314274A AU2002314274B2 (en) 2001-06-01 2002-05-29 Vaccination against the feline immunodeficiency virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/07275 2001-06-01
FR0107275A FR2825280B1 (fr) 2001-06-01 2001-06-01 Vaccination contre le virus de l'immunodeficience feline

Publications (2)

Publication Number Publication Date
WO2002096349A2 WO2002096349A2 (fr) 2002-12-05
WO2002096349A3 true WO2002096349A3 (fr) 2004-03-11

Family

ID=8863923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001809 Ceased WO2002096349A2 (fr) 2001-06-01 2002-05-29 Vaccination contre le virus de l'immunodeficience feline

Country Status (14)

Country Link
EP (1) EP1418941B9 (fr)
JP (1) JP2004535406A (fr)
AT (1) ATE473013T1 (fr)
AU (1) AU2002314274B2 (fr)
BR (1) BRPI0210229B1 (fr)
CA (1) CA2448620C (fr)
CZ (1) CZ305257B6 (fr)
DE (1) DE60236943D1 (fr)
DK (1) DK1418941T3 (fr)
ES (1) ES2348226T3 (fr)
FR (1) FR2825280B1 (fr)
PL (1) PL210450B1 (fr)
PT (1) PT1418941E (fr)
WO (1) WO2002096349A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US9925248B2 (en) 2013-08-29 2018-03-27 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030019A1 (fr) * 1994-04-29 1995-11-09 Pharmacia & Upjohn Company Vaccin contre le virus de l'immunodeficience feline
WO1998021354A1 (fr) * 1996-11-14 1998-05-22 Virogenetics Corporation Vecteurs d'expression a base de poxvirus contenant des inserts heterologues derives de lentivirus
WO2000077043A2 (fr) * 1999-06-10 2000-12-21 Merial Vaccins adn pour animaux de compagnie et de sport
EP1074625A2 (fr) * 1999-06-14 2001-02-07 Pfizer Products Inc. ADN vaccin contre le virus de l'immunodéficience chez les félins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030019A1 (fr) * 1994-04-29 1995-11-09 Pharmacia & Upjohn Company Vaccin contre le virus de l'immunodeficience feline
WO1998021354A1 (fr) * 1996-11-14 1998-05-22 Virogenetics Corporation Vecteurs d'expression a base de poxvirus contenant des inserts heterologues derives de lentivirus
WO2000077043A2 (fr) * 1999-06-10 2000-12-21 Merial Vaccins adn pour animaux de compagnie et de sport
EP1074625A2 (fr) * 1999-06-14 2001-02-07 Pfizer Products Inc. ADN vaccin contre le virus de l'immunodéficience chez les félins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
I. RAMSHAW ET AL.: "The prime-boost strategy: exciting prospects for improved vaccination", IMMUNOLOGY TODAY, vol. 21, no. 4, 2000, pages 163 - 165, XP002193913 *

Also Published As

Publication number Publication date
EP1418941A2 (fr) 2004-05-19
CA2448620C (fr) 2013-05-28
EP1418941B9 (fr) 2010-10-20
PL365742A1 (en) 2005-01-10
PL210450B1 (pl) 2012-01-31
WO2002096349A2 (fr) 2002-12-05
BRPI0210229B1 (pt) 2016-11-22
EP1418941B1 (fr) 2010-07-07
PT1418941E (pt) 2010-10-12
ATE473013T1 (de) 2010-07-15
CZ305257B6 (cs) 2015-07-08
DE60236943D1 (de) 2010-08-19
ES2348226T3 (es) 2010-12-01
AU2002314274B2 (en) 2008-03-20
CA2448620A1 (fr) 2002-12-05
DK1418941T3 (da) 2010-11-01
BR0210229A (pt) 2004-07-20
JP2004535406A (ja) 2004-11-25
CZ20033229A3 (cs) 2004-03-17
FR2825280A1 (fr) 2002-12-06
FR2825280B1 (fr) 2005-04-15

Similar Documents

Publication Publication Date Title
NO992369L (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
AU3844101A (en) Avirulent, immunogenic flavivirus chimeras
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
WO2004050856A3 (fr) Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
EP2269639A3 (fr) Formulations de vaccins contre la grippe dispositif pour administration intradermique
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
WO1997048370A3 (fr) Vaccins comprenant des genes de synthese
AP2000001828A0 (en) HIV-1 TAT, or derivatives thereof for prophylactic and therapeutic vaccination.
CZ15999A3 (cs) Formulace polynukleotidové vakciny koček
Kadkhodayan et al. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model
JP2004533208A5 (fr)
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
WO2008060385A3 (fr) Efficacité vaccinale améliorée par li-key
WO2004041851A3 (fr) Vaccin
WO2002096349A3 (fr) Vaccination contre le virus de l'immunodeficience feline
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003089571A3 (fr) Genes extrait de ehrlichia canis et vaccins contre cette bacterie
WO2005110492A3 (fr) Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
WO2005027844A3 (fr) Compositions issues d'un vaccin adn et leurs procedes d'utilisation
WO2002044323A3 (fr) Vecteurs pour exprimer des peptides hétérologues au niveau de la terminaison amino de la protéine d'enveloppe du potyvirus, procédé pour leur utilisation, végétaux ainsi infectés, et procédés de vaccination au moyen de ces vecteurs
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
WO2002000250A3 (fr) Vaccins hiv-1 et methodes de depistage correspondantes
Wardley et al. Feline immunodeficiency virus vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002740841

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2003-3229

Country of ref document: CZ

Ref document number: 2002314274

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2448620

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002592862

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: PV2003-3229

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002740841

Country of ref document: EP